Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: We describe the changing pattern of analgesic and new central acting drug (NCAD) use (pregabalin, duloxetine, milnacipran) in fibromyalgia and measure NCAD effectiveness in clinical practice. Methods: About 3123 US adult patients with fibromyalgia participated in an 11‐year longitudinal study of fibromyalgia outcomes. We assessed severity‐adjusted treatment prevalence and measured the effect of any use of NCAD on pain and fatigue, and functional status using the H ealth A ssessment Q uestionnaire (HAQ) disability index. Results: In 2010, 46.7% of patients used opioids, including 12.5% who used strong opioids. During the 11 years, severity‐adjusted strong opioid use increased from 6.3% to 11.7% and any opioid use from 40.0% to 46.6%. Nonsteroidal anti‐inflammatory drug (NSAID) use decreased from 74% to 44%. Tricyclic use dropped in half, from 27% to 15%, while NCAD use increased from less than 10% to 39%. The estimated 25th and 50th percentiles for NCAD discontinuation time were 1 and 2.5 years. Overall pain, fatigue and HAQ scores were unchanged over the 11 years. For patients treated with NCAD, pain scores were reduced significantly by 0.17 (0.03, 0.30) units following the start of NCAD, an improvement of 2.8%. Some sensitivity analyses showed improvements of up to 4.3%. There was no significant improvement in fatigue or functional status. Conclusions: There is a changing pattern of drug treatment in fibromyalgia, consisting mostly of decreased NSAID and amitriptyline use and an increase in NCAD. Drug costs are substantially higher because of NCAD use, but we found no evidence of clinical benefit for NCAD compared with prior therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006) · European Journal of Pain · doi:10.1016/j.ejpain.2005.06.009 · Cited by 5,486
Guidelines on the management of fibromyalgia syndrome – A systematic review
Häuser, W., Thieme, K., & Turk, D. C. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.01.006 · Cited by 347 · cited 5×
“However, the degree of efficacy is small, with effect sizes for pain in the neighbourhood of 0.35; and there is almost no effect on fatigue, a central and key symptom of fibromyalgia (Hauser et al., 2010a).”
BackgroundInfluentialSelf-citationComparative Efficacy and Harms of Duloxetine, Milnacipran, and Pregabalin in Fibromyalgia Syndrome
Häuser, W., Petzke, F., & Sommer, C. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.01.002 · Cited by 216 · cited 5×
“However, the degree of efficacy is small, with effect sizes for pain in the neighbourhood of 0.35; and there is almost no effect on fatigue, a central and key symptom of fibromyalgia (Hauser et al., 2010a).”
BackgroundInfluentialSelf-citationLong-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia
Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.001 · Cited by 54 · cited 2×
“Although some open-label extension data exist (Chappell et al., 2009; Mease et al., 2009; Murphy et al., 2009), open-label studies are inher- 585Eur J Pain 17 (2013) 581–586 © 2012 European Federation of International Association for the Study of Pain Chapters ently biased as to efficacy (Taylor…”
Background
Cited by
Häuser, W., Ablin, J., Fitzcharles, M.-A., Littlejohn, G., Luciano, J. V., Usui, C., & Walitt, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.22 · Cited by 505
Self-citationReview of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188
“Therefore, we refer to the results of FMS consumer reports [9,10], of cohort studies of patient databanks [24], and of administrative claims data [25] to better understand patterns of drug use in the general population.”
ResultSelf-citationAgger, J. L., Schröder, A., Gormsen, L. K., Jensen, J. S., Jensen, T. S., & Fink, P. K. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30126-8 · Cited by 52
Luciano, J. V., D’Amico, F., Cerdà-Lafont, M., Peñarrubia-María, M. T., Knapp, M., Cuesta-Vargas, A. I., Serrano-Blanco, A., & García-Campayo, J. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0451-y · Cited by 48
“[50] examined the changes in pharmacologic therapies that have occurred over the last decade in a wide sample of adult FM patients (N = 3,123).”
BackgroundLaroche, F., Guérin, J., Azoulay, D., Coste, J., & Perrot, S. (2019) · Revue du Rhumatisme · doi:10.1016/j.rhum.2018.01.002 · Cited by 13
Metadata
- Authors
- Wolfe, F., Walitt, B. T., Katz, R. S., Lee, Y. C., Michaud, K. D., & Häuser, W.
- Venue
- European Journal of Pain
- Publisher
- Wiley
- Published
- 2012-11-21
- Volume
- 17
- Issue
- 4
- Pages
- 581-586
- ISSN
- 1090-3801 (ISSN-L)
- 1532-2149
- OpenAlex
- W1554435410
- Cited by
- 56
- References
- 4
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. https://app.cochat.ai/papers/10.1002/j.1532-2149.2012.00234.x
- The paper
- Wolfe, F., Walitt, B. T., Katz, R. S., Lee, Y. C., Michaud, K. D., & Häuser, W. (2013). Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. European Journal of Pain. https://doi.org/10.1002/j.1532-2149.2012.00234.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.